secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2026-06-09T20:28:58+00:00
Accession:  0001193125-26-263831
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SL-325 Phase 1 shows 3.7% ADA, durable DR3 blockade; 96% of warrants exercised for ~$49.3M additional proceeds.
--------------------------------------------------------------------------------

- Phase 1: ADA detected in only 3.7% (2/54) of SL-325 recipients; low titer (≤16) with no PK/RO impact.
- Complete DR3 occupancy at all doses ≥0.1 mg/kg; PK modeling suggests >3 months blockade at doses ≥1 mg/kg.
- No serious TEAEs; all TRAEs Grade 1; no DR3 agonism or lymphocyte proliferation observed.
- RECEPTIVE-CD1 Phase 2b in Crohn's expected to start Q3 2026; primary endpoint endoscopic response at Week 12.
- Warrant exercise for ~50.6M shares (96% of Aug 2025 placement) yields ~$54.9M gross; cash runway into 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000119312526263831/0001193125-26-263831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000119312526263831/d120796d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-263831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer